Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in February 2015 at the end of the period of market exclusivity.

On 9 July 2001, orphan designation (EU/3/01/048) was granted by the European Commission to Elan Pharma International Ltd, Ireland, for ziconotide (intraspinal use) for the treatment of chronic pain requiring intraspinal analgesia.

The sponsorship was transferred to Eisai Limited, United Kingdom, in September 2006.For administrative updates: choose or delete if not applicable.

Ziconotide (intraspinal use) has been authorised in the EU as Prialt since 21 February 2005.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Ziconotide (intraspinal use)
Medicine name
Disease / condition
Treatment of chronic pain requiring intraspinal analgesia
Date of first decision
EU designation number

Sponsor's contact details

Eisai Limited
European Knowledge Centre
Mosquito Way
Herts AL10 9SN
United Kingdom
Tel. +44 (0)20 8600 1400
Fax +44 (0)20 8600 1504

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating